Critical Comparison: Crescent Biopharma (NASDAQ:CBIO) versus C4 Therapeutics (NASDAQ:CCCC)

C4 Therapeutics (NASDAQ:CCCC) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares C4 Therapeutics and Crescent Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Crescent Biopharma	N/A	-101.50%	-86.86%

Institutional and Insider Ownership

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

C4 Therapeutics has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for C4 Therapeutics and Crescent Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	0	4	0	2.60
Crescent Biopharma	1	1	2	2	2.83

C4 Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 118.42%. Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 52.50%. Given C4 Therapeutics’ higher probable upside, research analysts clearly believe C4 Therapeutics is more favorable than Crescent Biopharma.

Valuation & Earnings

This table compares C4 Therapeutics and Crescent Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.04 million	12.32	-$104.99 million	($1.00)	-3.51
Crescent Biopharma	$11.88 million	60.67	-$153.94 million	($6.72)	-2.89

C4 Therapeutics has higher revenue and earnings than Crescent Biopharma. C4 Therapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

C4 Therapeutics beats Crescent Biopharma on 9 of the 15 factors compared between the two stocks.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.